United Pharm - Asset Resilience Ratio
United Pharm (033270) has an Asset Resilience Ratio of 22.90% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how United Pharm's Asset Resilience Ratio has changed over time. Check United Pharm (033270) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down United Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see United Pharm stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩128.97 Billion | 22.9% |
| Total Liquid Assets | ₩128.97 Billion | 22.90% |
Asset Resilience Insights
- Good Liquidity Position: United Pharm maintains a healthy 22.90% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
United Pharm Industry Peers by Asset Resilience Ratio
Compare United Pharm's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Zhejiang Garden Bio-chemical High-tech Co Ltd
SHE:300401 |
Drug Manufacturers - Specialty & Generic | 5.09% |
|
KPC Pharmaceuticals Inc
SHG:600422 |
Drug Manufacturers - Specialty & Generic | 16.37% |
Annual Asset Resilience Ratio for United Pharm (2011–2025)
The table below shows the annual Asset Resilience Ratio data for United Pharm.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 22.48% | ₩116.77 Billion ≈ $79.13 Million |
₩519.49 Billion ≈ $352.05 Million |
+1.67pp |
| 2024-12-31 | 20.81% | ₩98.61 Billion ≈ $66.83 Million |
₩473.93 Billion ≈ $321.17 Million |
-6.31pp |
| 2023-12-31 | 27.12% | ₩127.14 Billion ≈ $86.16 Million |
₩468.86 Billion ≈ $317.74 Million |
-0.58pp |
| 2022-12-31 | 27.70% | ₩115.74 Billion ≈ $78.43 Million |
₩417.89 Billion ≈ $283.20 Million |
+11.28pp |
| 2021-12-31 | 16.41% | ₩62.37 Billion ≈ $42.27 Million |
₩380.03 Billion ≈ $257.54 Million |
+1.20pp |
| 2020-12-31 | 15.21% | ₩53.76 Billion ≈ $36.44 Million |
₩353.43 Billion ≈ $239.52 Million |
+3.71pp |
| 2019-12-31 | 11.50% | ₩38.09 Billion ≈ $25.81 Million |
₩331.24 Billion ≈ $224.48 Million |
-0.82pp |
| 2018-12-31 | 12.32% | ₩37.19 Billion ≈ $25.20 Million |
₩301.95 Billion ≈ $204.63 Million |
+0.09pp |
| 2017-12-31 | 12.23% | ₩32.51 Billion ≈ $22.03 Million |
₩265.80 Billion ≈ $180.13 Million |
+1.69pp |
| 2016-12-31 | 10.54% | ₩24.70 Billion ≈ $16.74 Million |
₩234.22 Billion ≈ $158.73 Million |
+5.15pp |
| 2014-12-31 | 5.40% | ₩11.72 Billion ≈ $7.94 Million |
₩217.10 Billion ≈ $147.13 Million |
+5.08pp |
| 2013-12-31 | 0.32% | ₩615.09 Million ≈ $416.84K |
₩193.54 Billion ≈ $131.16 Million |
-4.67pp |
| 2012-12-31 | 4.99% | ₩9.36 Billion ≈ $6.34 Million |
₩187.58 Billion ≈ $127.12 Million |
+4.76pp |
| 2011-12-31 | 0.23% | ₩384.56 Million ≈ $260.61K |
₩170.09 Billion ≈ $115.26 Million |
-- |
About United Pharm
Korea United Pharm Inc. engages in the manufacture and sale of pharmaceutical products in South Korea. It offers products in the areas of respiratory system, musculo-skeletal system, gastro-intestinal tract system, cardiovascular system, anti-cancer, anti-infectives, allergy, immune system, central nervous system, and other diseases, as well OTC drugs. The company also exports its products to app… Read more